FDAnews
www.fdanews.com/articles/142683-multiple-myeloma-phase-iii-trial-mdash-vorinostat-achieved-primary-endpoint

Multiple Myeloma Phase III Trial — Vorinostat Achieved Primary Endpoint

December 21, 2011
MSD announced the results of their Phase III study of vorinostat at the 53rd Annual Meeting of the American Society of Hematology. Vorinostat, designed for treatment in patients with progressive multiple myeloma, has met its primary endpoint in a Phase III study for investigational use in combination with bortezomib.
Medical News Today